Description:

Size: 100ul

Catalog no.: bs-12676R-A488

Price: 380 EUR

Product details

Modification Site

None

Target Antigen

PRAM1

French translation

anticorps

Tested applications

IF(IHC-P)

Clonality

Polyclonal

Modification

Unmodified

Excitation emission

499nm/519nm

Concentration

1ug per 1ul

Conjugation

Alexa Fluor

Conjugated with

ALEXA FLUOR® 488

Crossreactivity

Human, Mouse, Rat

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Category

Conjugated Primary Antibodies

Also known as

Anti-PRAM1 PAb ALEXA FLUOR 488

Host Organism

Rabbit (Oryctolagus cuniculus)

Specificity

This is a highly specific antibody against PRAM1.

Long name

PRAM1 Polyclonal Antibody, ALEXA FLUOR 488 Conjugated

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human PRAM1

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Synonyms

PML RAR; PML RARA regulated adaptor molecule 1; PML RARA target gene encoding an Adaptor Molecule 1; PML-RARA-regulated adapter molecule 1; PRAM 1; PRAM; PRAM-1; PRAM_HUMAN; PRAM1.

Properties

For facs or microscopy Alexa 1 conjugate.Alexa Fluor 488 has the same range to that of fluorescein isothiocyanate (FITC), yet the Anti-PRAM1 has a very high photo stability. As a result of this photo stability, it has turned into an antibody for fluorescent microscopy and FACS FLOW cytometry. It is distinguished in the FL1 of a FACS-Calibur or FACScan. Also Alexa Fluor 488 is pH stable.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Complete remission of acute promyelocytic leukemia can be achieved by treating patients with retinoic acid, and PML-RAR-a (promyelocytic leukemia-retinoic acid receptor alpha fusion protein) plays a major role in mediating retinoic acid effects in leukemia cells. The retinoic acid-induced gene, PRAM-1 (PML-RAR-a target gene encoding an adaptor molecule 1) encodes an adaptor protein which is expressed and modulated during normal human myelopoiesis. PRAM-1 expression is hindered by expression of PML-RAR-a. The 718 amino acid PRAM-1 protein contains eight N-terminal proline-rich repeats and several proline residues that are clustered as type I or type II SH3 recognition motifs. PRAM-1 demonstrates expression in hematopoietic tissues and lung.